摘要 |
The present disclosure relates in general to methods for recombinantly producing soluble, active IgA proteases (e.g., IgA1 proteases) in host cells (e.g., bacterial cells), and methods for using IgA proteases (e.g., IgA1 proteases) produced by the methods to treat IgA deposition disorders (e.g., IgA nephropathy).
|